Skip to Content

Naratriptan Pregnancy and Breastfeeding Warnings

Naratriptan is also known as: Amerge

Naratriptan Pregnancy Warnings

Animal tests have reported developmental toxicity (embryolethality, fetal abnormalities, pup mortality, and offspring growth retardation) and dose-related increases in embryonic death, and fetal structural variations (incomplete/irregular ossification of skull bones, sternebrae, and ribs). High doses in animals have been reported to have led to fused sternebrae, increased incidences of embryonic death, and fetal variations (major blood vessel variations, supernumerary ribs, and incomplete skeletal ossification). Offspring of rats whose dams received doses of 10, 60, or 340 mg/kg/day during late gestation and lactation have demonstrated behavioral impairment (tremors), and decreased viability and growth at doses of 60 mg/kg or greater. There are no controlled data in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: B3 US FDA pregnancy category: C

See references

Naratriptan Breastfeeding Warnings

Breastfeeding should be avoided for 24 hours after administration of this drug Excreted into human milk: Unknown Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Amerge (naratriptan)." Glaxo Wellcome, Research Triangle Park, NC.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Amerge (naratriptan)." Glaxo Wellcome, Research Triangle Park, NC.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide